ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
Abivax S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$87.49−0.64 (-0.73%)
Close on Oct 19, 2026
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 8.75 | |
| Interest coverage | – | – | -2.2× | |
| Diluted shares | – | – | 70M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Abivax generated €511.32M from operations and spent €1.38M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€511.32M
Used
€1.38M
Capital expenditure€1.38M100%Dividends€00%Share buybacks€00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 3 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-€161.13M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-€161.13M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.82 → 8.75
- No dilutionShare count did not rise63M → 70M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –